Avalo Therapeutics (AVTX) Shares Issued (2014 - 2026)

Avalo Therapeutics has reported Shares Issued for 12 years, with the latest figure at $2.2 million in Q1 2026.

• For the quarter ending Q1 2026, Shares Issued changed N/A year-over-year to $2.2 million; the trailing twelve-month figure through Mar 2026 stood at $2.2 million (down 93.64% YoY), and the FY2025 full-year result was $23000.0, down 99.98% from the prior year.
• Shares Issued for Q1 2026 stood at $2.2 million, up from $23000.0 in the prior quarter.
• The five-year high for Shares Issued was $142.7 million in Q4 2024, with the low at -$108.1 million in Q2 2024.
• Historically, Shares Issued has averaged $16.3 million across 5 years, with a median of $1.1 million in 2023.
• The largest YoY upside for Shares Issued was 662.2% in 2024 against a maximum downside of 161443.28% in 2024.
• Avalo Therapeutics' Shares Issued stood at -$14.8 million in 2022, then surged by 226.24% to $18.7 million in 2023, then soared by 662.2% to $142.7 million in 2024, then tumbled by 99.98% to $23000.0 in 2025, then soared by 9369.57% to $2.2 million in 2026.
• The last three Shares Issued figures came in at $2.2 million (Q1 2026), $23000.0 (Q4 2025), and $142.7 million (Q4 2024), per Business Quant data.